Trince

Trince is a biotech startup based in Belgium, founded in 2014. The company focuses on advancing cell-based science and therapeutics through its LumiPore transfection platform, leveraging laser exposure and photothermal nanoparticles to facilitate the delivery of molecules into cells. This technology, protected by a portfolio of pending patents, enables the gentle and efficient delivery of various effector molecules, including nucleic acids and proteins, into a wide range of cell types. Notably, it can target hard-to-transfect cells, such as immune cells for cell therapies, enhancing the therapeutic quality of the final cell product. Trince recently secured €4.00M in a Seed Round investment on 04 December 2021, with funding attributed to QBIC and Novalis Biotech. The company's dedication to enabling precise transfections showcases its potential to make significant contributions to the biopharma and biotechnology industries. Learn more about Trince at www.trincebio.com.